Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CD40 deja vu

CD40 ligand is a logical target for certain autoimmune diseases and cancers, as it is primarily expressed on CD4 T cells and enhances the co-stimulatory function of antigen presenting cells, including dendritic cells, B cells and monocytes. However, when Idec Pharmaceutical Corp. last week halted

Read the full 451 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE